Beneficial role for supplemental vitamin D treatment in chronic urticaria

Post on February 17, 2014 by André Broussard, D.C.

A randomized studyANAI Home
Annals of Allergy, Asthma, and Immunology, 04/29/2014 > Clinical Article

Rorie Z, et al. – Add–on therapy with high–dose vitamin D3 (4,000 IU/d) could be considered a safe and potentially beneficial immunomodulator in patients with chronic urticaria.

  • In a prospective, double-blinded, single-center study, 42 subjects with chronic urticaria were randomized to high (4,000 IU/d) or low (600 IU/d) vitamin D3 supplementation for 12 weeks.
  • All subjects were provided with a standardized triple-drug therapy (cetirizine, ranitidine, and montelukast) and a written action plan.
  • Data on USS scores, medication use, blood for 25-hydroxyvitamin D, and safety measurements were collected.

Results

  • Triple-drug therapy decreased total USS scores by 33% in the first week.
  • There was a further significant decrease (40%) in total USS scores in the high, but not low, vitamin D3 treatment group by week 12.
  • Compared with low treatment, the high treatment group demonstrated a trend (P = .052) toward lower total USS scores at week 12, which was driven by significant decreases in body distribution and number of days with hives.
  • Beneficial trends for sleep quality and pruritus scores were observed with high vitamin D3.
  • Serum 25-hydroxyvitamin D levels increased with high vitamin D3 supplementation, but there was no correlation between 25-hydroxyvitamin D levels and USS scores.
  • There was no difference in allergy medication use between groups.
  • No adverse events occurred.
Comments Are Closed